Liquidia Corporation Q2 2025 Earnings Recap

Liquidia Corporation reported strong initial commercial success for YUTREPIA, with over 900 prescriptions and 550 patient starts within weeks of launch, indicating robust market demand for its innovative prostacyclin therapy.

Key Takeaways

• YUTREPIA has achieved over 900 unique patient prescriptions and 550 patient starts within the first 11 weeks, showcasing unprecedented adoption in the prostacyclin market.
• A 75% conversion rate from prescriptions to patient starts in the first 6 weeks reflects strong physician support and patient acceptance of the therapy.
• Preliminary safety data from the ASCENT study highlights favorable tolerability, with only 18.5% of patients discontinuing treatment at 16 weeks, significantly better than competitors.
• Improvements in patient dosing and a median increase of 31.5 meters in 6-minute walk distance at week 16 illustrate YUTREPIA's efficacy in real-world conditions.
• Health care providers have positively received comprehensive market access programs, providing co-pay assistance and free trial vouchers to enhance patient access.